In silico identification and pharmacological evaluation of novel endocrine disrupting chemicals that act via the ligand-binding domain of the estrogen receptor alpha.

Article Details

Citation

McRobb FM, Kufareva I, Abagyan R

In silico identification and pharmacological evaluation of novel endocrine disrupting chemicals that act via the ligand-binding domain of the estrogen receptor alpha.

Toxicol Sci. 2014 Sep;141(1):188-97. doi: 10.1093/toxsci/kfu114. Epub 2014 Jun 13.

PubMed ID
24928891 [ View in PubMed
]
Abstract

Endocrine disrupting chemicals (EDCs) pose a significant threat to human health, society, and the environment. Many EDCs elicit their toxic effects through nuclear hormone receptors, like the estrogen receptor alpha (ERalpha). In silico models can be used to prioritize chemicals for toxicological evaluation to reduce the amount of costly pharmacological testing and enable early alerts for newly designed compounds. However, many of the current computational models are overly dependent on the chemistry of known modulators and perform poorly for novel chemical scaffolds. Herein we describe the development of computational, three-dimensional multi-conformational pocket-field docking, and chemical-field docking models for the identification of novel EDCs that act via the ligand-binding domain of ERalpha. These models were highly accurate in the retrospective task of distinguishing known high-affinity ERalpha modulators from inactive or decoy molecules, with minimal training. To illustrate the utility of the models in prospective in silico compound screening, we screened a database of over 6000 environmental chemicals and evaluated the 24 top-ranked hits in an ERalpha transcriptional activation assay and a differential scanning fluorimetry-based ERalpha binding assay. Promisingly, six chemicals displayed ERalpha agonist activity (32nM-3.98muM) and two chemicals had moderately stabilizing effects on ERalpha. Two newly identified active compounds were chemically related beta-adrenergic receptor (betaAR) agonists, dobutamine, and ractopamine (a feed additive that promotes leanness in cattle and poultry), which are the first betaAR agonists identified as activators of ERalpha-mediated gene transcription. This approach can be applied to other receptors implicated in endocrine disruption.

DrugBank Data that Cites this Article

Drug Targets
DrugTargetKindOrganismPharmacological ActionActions
DobutamineEstrogen receptor alphaProteinHumans
Unknown
Not AvailableDetails
RactopamineEstrogen receptor alphaProteinHumans
Unknown
Not AvailableDetails